BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30

• Drug Development

  ASCO2016: Gamida Cell Presents Data From Phase 1/2 Study Of Nicord For High Risk Hematological Malignancies At ASCO 2016

  June 6, 2016

   · 

  4 min read
• Drug Development

  ASCO2016: Early-Phase Immuno-Oncology Studies Of Eli Lilly’s ALIMTA (Pemetrexed) And CYRAMZA (Ramucirumab) With Merck & Co.'s KEYTRUDA (Pembrolizumab) Show Encouraging Results In Non-Small Cell Lung Cancer

  June 6, 2016

   · 

  23 min read
• Drug Development

  ASCO2016: AbbVie Builds Upon Robust Body Of IMBRUVICA (Ibrutinib) Data With Phase 3 Longer-Term Studies In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma Presented At The American Society Of Clinical Oncology (ASCO) Annual Meeti

  June 6, 2016

   · 

  13 min read
• Drug Development

  Stealth Biotherapeutics Reports Positive Results For Primary Mitochondrial Myopathy Trial

  June 6, 2016

   · 

  3 min read
• Drug Development

  ASCO2016: Mylan-BioCon’s Biosimilar Cancer Drug Comparable to Roche’s Herceptin

  June 6, 2016

   · 

  10 min read
• Drug Development

  ASCO2016: Celator Pharma Presented Phase 3 Trial Results In Patients With High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS (CPX-351) Significantly Improved Overall Survival

  June 6, 2016

   · 

  9 min read
• Drug Development

  ASCO2016: Kite Pharma/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions In Advanced Non-Hodgkin Lymphoma

  June 6, 2016

   · 

  4 min read
• Biotech Beach

  Amgen Announces Launch Of KYPROLIS (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers

  June 6, 2016

   · 

  17 min read
• Drug Development

  ASCO2016: AstraZeneca PLC LYNPARZA (Olaparib): Latest Data Suggest Potential Overall Survival Advantage In Patients With Platinum Sensitive Ovarian Cancer

  June 6, 2016

   · 

  12 min read
• Drug Development

  ASCO2016: AstraZeneca PLC’s Durvalumab Monotherapy Demonstrates Efficacy in Urothelial Bladder Cancer

  June 6, 2016

   · 

  8 min read